Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant

December 6, 2021

The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

November 29, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 23, 2021

Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

November 10, 2021

Gritstone Reports Third Quarter 2021 Financial Results and Business Update

November 3, 2021

Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events

October 25, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2021

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

September 20, 2021

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

September 17, 2021

Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent

September 17, 2021

Pagination

First page
Previous page
…
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
…
Next page
Last page

© 2024 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top